Paul R. Gugliuzza’s faculty profile
Newsweek October 27, 2025
America’s Largest Lobbying Group Turns on Trump Admin Over H-1B Visas
Professor Paul Gugliuzza explains that the decision by the U.S. Chamber of Commerce to file a lawsuit against the Trump administration over a $100,000 H-1B visa fee in a federal court in Washington, D.C., stands out because of a broad trend of system abuse that makes normal cases look exceptional.
Bloomberg Law October 23, 2025
US Chamber Turns Trump Foe in Rare Split Over $100,000 H-1B Fee
Professor Paul Gugliuzza reflects on the recent actions of the US Chamber of Commerce challenging the Trump administration.
PATENTLYO October 8, 2025
Have we Reached the Shenanigans Threshold?
Professor Paul Gugliuzza comments on the thin statutory basis for the broad discretionary powers of USPTO Director John Squire following his recent decision in Interactive Communications International, Inc. v. Blackhawk Network.
Law360 August 5, 2025
Law Profs Urge 11th Circ. To Toss Judge-Shopping Sanctions
Professor Paul Gugliuzza joined six other law professors in an amicus brief urging the Eleventh Circuit to overturn sanctions against three attorneys accused of judge shopping, arguing the presiding judge lacked jurisdiction, the order violated federal procedural rules, and federal law does not prohibit the practice.
PATENTLYO July 31, 2025
Ideology, Expertise, and the Evolving Federal Circuit
Professor Paul Gugliuzza's co-authored study, "Expertise, Ideology, and Dissent"—analyzing how judicial expertise, ideological alignment, and institutional factors shape voting and dissent at the U.S. Court of Appeals for the Federal Circuit—was referenced in an article about the Federal Circuit’s composition.
Austin American-Statesman July 26, 2025
Even at the U.S. patent office, an erosion of norms under Trump | Opinion
Professor Paul Gugliuzza argues that under President Trump, the U.S. Patent and Trademark Office has become politicized with staff and rule changes that weaken the system by prioritizing speed and control over transparency and patent quality.
PatentlyO July 8, 2025
Corcept v. Teva Oral Argument: Infringement by Drug Label, Again
Professor Paul Gugliuzza warns that the Federal Circuit’s growing acceptance of “infringement by label” could chill generic drug competition by holding companies liable for patent infringement based on FDA-required language on their product labels.